Kornimate/medical-research-clean huggingface dataset:
optimizing assisted communication devices for children with motor impairments using a model of information rate and channel capacity

Conditions: Cerebral Palsy

Summary: for children who depend on devices to communicate, the rate of communication is a primary determinant of success. for children with motor impairments, the rate of communication may be limited by inability to contact buttons or cells rapidly or accurately. it is therefore essential to know how to adjust the device interface in order to maximize each child's rate of communication. the optimal rate of communication is determined by the channel capacity, which is the maximum value of the information rate for all possible keyboard button or cell layouts for the communication device. we construct a mathematical model for the information rate based on the relationship between movement time and the number of buttons per screen, the size of the buttons, and the length of a sequence of buttons that must be pressed to communicate each word in the vocabulary. we measure the parameters of the model using a custom-programmed touch-screen interface.


Eligibility criteria:
inclusion criteria:- use of dynavox ability to follow two-step commands impairment in arm function exclusion criteria:- increased risks of study
therapists to administer contingency management-therapist phase - 1

Conditions: Substance Abuse

Summary: the purpose of this study is to train therapists to administer contingency management (cm). this project will train up to 42 community-based treatment providers about the rationale for and the specifics of administering cm. initial training will occur in 2-day workshops, followed by weekly supervision in delivery of cm with test cases. we expect that the majority of therapists will achieve high levels of competence and adherence in administering cm treatment within 3-5 test cases, as measured by ratings of audiotapes. to examine the efficacy of cm, each therapist who achieves adherence and competence in delivering cm will administer standard treatment alone or standard treatment plus cm to substance-abusing outpatients. in the cm condition, patients will have the opportunity to win prizes for submission of negative samples, and the treatment will be in effect for 12 weeks. in total, up to 200 patients will be randomly assigned to one of the two conditions. a research evaluator will conduct follow-up assessments, scheduled for 3, 6 and 9 months after treatment initiation.


Eligibility criteria:
inclusion criteria: therapists who volunteer must have: * at least one-year experience treating substance abusers, and at least 6 months employment at that center * must commit to being available for both the workshop and individual training * must be willing to allow random assignment of their patients to cm and non-cm treatments

Keywords: contingency management substance abuse treatment
halos: a safety, tolerability, pharmacokinetics and pharmacodynamics study of multiple ascending doses of ion582 in participants with angelman syndrome

Conditions: Angelman Syndrome

Summary: the purpose of this study is to evaluate the safety and tolerability of ascending doses of ion582 administered intrathecally in participants with angelman syndrome.

this is a phase 1-2a, open-label study consisting of 3 parts. part 1 is a multiple ascending dose (mad) study, consisting of a 13-week mad treatment period and a minimum 12-week but up to 32-week post-mad follow-up period. part 2 is a multi-center 49-week study where participants who completed part 1 will receive it bolus doses of ion582 followed by a minimum 12-week part 2 follow up period. part 3 extends the treatment period for participants who completed part 2 for up to an additional 3 years followed by a 32-week post-lte follow up period. the study will enroll approximately 44, and up to 55, participants.

Eligibility criteria:
inclusion criteria: 1. participant has a documented and certified diagnosis of angelman syndrome (as) (ubiquitin-protein ligase e3a \[ube3a\] deletion or ube3a mutation) 2. male or female between the ages of 2-50 years of age, with signed informed consent from parent(s) or legal guardian(s) 3. currently receiving stable standard of care treatments such as, stable doses of anti-epileptic medication, behavioral management medications, sleep medications, gabapentin, cannabidiol, and including special diets, supplements or nutritional support for at least 3 months prior to first dose. 4. follow good study practice and not participate in the sharing of personal or study information on social media platforms, such as any website or social media site (e.g., facebook, instagram, twitter, youtube, etc.) until notified that the study is completed. exclusion criteria: 1. has documented molecular as confirmation of paternal uniparental disomy (upd) or imprinting defect (id). 2. any clinically significant (cs) cardiovascular, endocrine, hepatic, renal, pulmonary, gastrointestinal, neurologic, malignant, metabolic, psychiatric, or other condition that, in the judgment of the investigator, will pose a safety risk, will make the patient unsuitable for participation in, and/or unable to complete the study procedures. has poorly controlled seizures as determined by the investigator or has documented status epilepticus in the past 6 months that could pose a safety risk while on study. 3. known bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture. previous treatment with an oligonucleotide (including small interfering ribonucleic acid, antisense oligonucleotide \[asos\]). covid-19 vaccinations are allowed. 4. any prior use of gene therapy. have any other conditions, which, in the opinion of the investigator would make the participant unsuitable for inclusion or could interfere with the participant taking part in or completing the study.
relationship between tooth decay and trabecular bone

Conditions: Dental Caries in Children; Pediatric Patients; Radiology

Summary: chewing, a movement that matures with experiences, has effects on the growth and development of the stomatognathic system. tooth decay, which is known to have effects on chewing, can affect the jaw bone due to its indirect effect on the mechanical forces transmitted to the jaw bone. this study was aimed to evaluate the relationship between dental caries and jaw bone trabeculation during the growth and development processes in children by fractal dimension analysis method. 40 patients with deep-dentin caries / apical rarefying osteitis on the right or left side, 40 patients with deep-dentin caries / apical rarefying osteitis on either the right and left sides and 40 patients without deep-dentin caries / apical rarefying osteitis between 8-13 ages were randomly selected. digital panoramic images of the selected patients were analyzed with fractal dimension analysis.


Eligibility criteria:
inclusion criteria: * panoramic radiographs of systemically healthy 8-13 years-old patients, * who applied to the clinic between january 2018 and april 2020 were retrospectively scanned. * patients with 1st molars whose root development was completed and the 2nd molars not erupted yet were included. exclusion criteria: * patients with temporomandibular joint disorders, any systemic disease, exposed to trauma in the area to be measured, received orthodontic treatment for the last 2 years or had an ongoing orthodontic treatment, unilateral / bilateral cross-bite and had parafunctional habits in their anamnesis were excluded.

Keywords: disturbances in dental development fractal analysis pediatric patients radiology
the relationship between blood pressure and arterial stiffness in hfpef patients with different levels of obesity

Conditions: Heart Failure With Preserved Ejection Fraction

Summary: heart failure with preserved ejection fraction (hfpef) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and arteriosclerosis. studies have found that hypertension and obesity are respectively associated with increased arterial stiffness. however, there is still no research investigating the the relationship between blood pressure and arterial stiffness in hfpef patients with different levels of obesity.

before the 21st century, heart failure with preserved ejection fraction (hfpef) was considered as a disease with simple diastolic dysfunction, but after the 21st century, hfpef was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and arteriosclerosis. other studies have found that hypertension and obesity are respectively associated with increased arterial stiffness. however, there is still no research investigating the the relationship between blood pressure and arterial stiffness in hfpef patients with different levels of obesity.

Eligibility criteria:
inclusion criteria: * adult aged \>=18years old; * diagnosed with hfpef. diagnostic criteria including: 1. left ventricular ejection fraction ≥50%； 2. with the symptoms and/or signs of heart failure； 3. bnp≥35 pg/ml and/or ntprobnp≥125 pg/ml； 4. at least one additional criterion: relevant structural heart disease(lvh and/or lae) or diastolic dysfunction exclusion criteria: * lvef less than 45% at any time; * severe liver failure; * other causes of shortness of breath, such as severe pulmonary disease or severe chronic obstructive pulmonary disease; * primary pulmonary hypertension; * severe valvular disease of the left heart; * chronically bedridden or incapacitated; * age \<18 years old.

Keywords: obesity the level of blood pressure arterial stiffness
pilot study of apd209 in cancer cachexia

Conditions: Cancer-related Cachexia

Summary: primary objective: to assess the efficacy of apd209 in adult patients with active cachexia associated with advanced malignancy and not caused by simple starvation. secondary objective: to assess the safety of apd209 in patients with advanced malignancy and active cachexia.


Eligibility criteria:
inclusion criteria: * involuntary loss of weight of \>= 2% in 2 months or \>= 5% in 6 months, and ongoing in recent weeks, without (or with successfully treated) secondary causes of impaired oral nutritional intake (simple starvation).

Keywords: cachexia neoplasms
trial to evaluate the immune response to opv when administered concomitantly with caiv-t to healthy children.

Conditions: Influenza

Summary: phase iii trial to evaluate the immune response to oral poliovirus vaccine (opv) when administered concomitantly with caiv-t to healthy children.


Eligibility criteria:
inclusion criteria: * who are aged at least 6 months and less than 36 months of age at the time of first vaccination * who have received a full primary vaccination schedule consisting of three doses of opv in the first year of life * who are in good health as determined by medical history, physical examination and clinical judgement * whose parent(s)/legal guardian(s) have provided written informed consent after the nature of the study has been explained * who, along with their parent(s)/legal guardian(s), will be available for duration of the trial (3 months) * whose parent(s)/legal guardian(s), can be reached by study staff for the post-vaccination contacts \[telephone, clinic or home visit\]. exclusion criteria: * whose parent(s)/legal guardian(s) are perceived to be unavailable or difficult to contact for evaluation or study visits during the study period * with any serious chronic disease (e.g., with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease * with down's syndrome or other known cytogenetic disorders * with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids (see section 4.2.1) * who received any blood products, including immunoglobulin, in the period from six months prior to vaccination through to the conclusion of the study * for whom there is intent to administer any other investigational vaccine or agent from one month prior to enrollment through to the conclusion of the study * have an immunosuppressed or an immunocompromised individual living in the same household * who, at any time prior to entry into this study, received a dose of any influenza vaccine (commercial or investigational) * with a documented history of hypersensitivity to egg or egg protein or any other component of the assigned study vaccine * who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two weeks prior to vaccination or for which use is anticipated during the study * with any medical conditions that in the opinion of the investigator might interfere with interpretation of the study results. if any of these criteria are met following enrollment, the subject will be excluded from subsequent vaccine dosing. note: pregnancy in a household member or any person who has regular contact with the subject is not a contraindication to the enrollment or ongoing participation of the subject in the study.
clinical trial of traditional chinese diaoshi jifa therapy of meniere's disease

Conditions: Meniere's Disease

Summary: the hypothesis of this study is that diaoshi jifa reduces the symptoms, such as dizziness in patients with meniere's disease.

created by dr. diao, diaoshi jifa is a well-known traditional chinese medicine approach to treat dizziness in patients with chronic diseases. the investigators designed this randomized clinical trial to examine whether diaoshi jifa significantly decreases dizziness in patients with meniere's disease. there are 2 arms in this trial: one arm is diaoshi jifa plus conventional western medical treatment, another is conventional western medical treatment only. the dizziness handicap inventory (dhi) will be used to evaluate the treatment effect.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of probable meniere's disease 2. must be able to receive manual treatment 3. dizziness patients receiving other treatment longer than 5 days before entering the study. exclusion criteria: 1. patients with critical illness of internal medicine and surgery 2. patients with spinal disease or other conditions that cannot receive manual treatment.

Keywords: dizziness meniere's disease diaoshi jifa therapy
a prospective comparison of ultrasound-guided percutaneous platelet-rich plasma injection

Conditions: Tendinosis; Tendinitis

Summary: the purpose of this study is to determine the effectiveness of various treatment soft tendinosis also known as tendinitis.

currently there are three treatments that are considered standard of care; rest, tenotomy and tenotomy with injections of platelet-rich plasma (prp). tenotomy is performed by passing a needle through the abnormal tendon repeatedly until the needle has passed through all areas of the abnormal tendon with softening of the tendon. tenotomy with prp injections is performed in the same manner but includes an injection of platelet-rich plasma (prp) into the tendon. this study will evaluate the effectiveness of tenotomy versus prp treatment.

Eligibility criteria:
inclusion criteria: * adult subjects with a diagnosis of tendinosis of the hip. * adult subjects who have been referred to dr. jacobson for the treatment of tendinosis by tenotomy. exclusion criteria: * pregnancy * risk of bleeding due to anticoagulant medication * presence of malignancy * steroid injection less than 3 months before enrollment
the contributions of the multidisciplinary management of prosthesis knee infections in a reference center: a retrospective study about 52 cases.skin coverage in a reference center: a retrospective study about 52 cases

Conditions: Knee Joint Prosthesis Infection; Flap Necrosis; Skin Graft Complications

Summary: acute and chronic infection of knee joint prosthesis can have several outcomes, the most feared of which is trans-femoral amputation. in order to save the limb while maintaining function, the management of these infections involves several specialists. orthopedic surgeons are on the front line for carrying out bacteriological samples as well as for changing the material when necessary. the infectiologists coordinate this care by supervising each of the interventions by an antibiotic therapy adapted to the germs and by ensuring the occurrence of adverse events related to the treatment. plastic surgeons intervene when the skin cover of the knee is deemed to be precarious or when there is an identified loss of substance that could affect the prognosis of the prosthesis. the main objective of our study is to evaluate the success rate of skin coverage and functional recovery for patients cured of their infection. the secondary objective is the identification of risk factors for skin coverage in this population.


Eligibility criteria:
inclusion criteria: * patients with a prosthesis knee infection whose management requires skin covering plastic surgery * surgical procedures performed at the croix rousse hospital exclusion criteria: * none

Keywords: knee joint prosthesis flap skin graft
biomarkers of acrylamide, glycidol, pops, pfas and disease outcomes and omics signatures

Conditions: Disease; Cardiovascular Diseases; Cancer; Environmental Exposure

Summary: the aim of the project is to assess the associations between biomarkers of acrylamide and glycidol exposure and disease outcomes in a case-cohort study based on two prospective cohorts with biobanks. the investigators also aim to assess the exposure-affected omics signatures and molecular pathways underlying disease development (specifically cardiovascular diseases such as myocardial infarction and stroke and cancer such as breast-, endometrial and colorectal cancer) for these exposures along with persistent organic pollutants (pops) and per- and polyflouroalkyl substances (pfas) using a prospective cohort study utilizing and integrating various 'omics' technologies.


Eligibility criteria:
inclusion criteria: * 60yo: men and women of 60 years old residing in stockholm * smc-c: women residing in uppsala exclusion criteria: * subjects will be excluded if they had the outcome under investigation at baseline
local infiltration analgesia following unicompartmental knee arthroplasty

Conditions: Postoperative Pain

Summary: the primary aim of this study is to evaluate if intra- and postoperative administration of ropivacaine, ketorolac and epinephrine into the operating field would affect hospital stay. secondary end-points are morphine consumption, pain intensity and side effects. in an attempt to assess the safety of this technique, knee function and patient satisfaction scores are assessed up to 6 months after surgery.

postoperative pain is often severe following knee arthroplasty. recently, a local infiltration analgesia (lia) technique was developed by drs kerr and kohan in sydney, australia. with this lia-technique, a long-acting local anesthetic (ropivacaine), a nonsteroidal anti-inflammatory drug (ketorolac), and epinephrine are infiltrated intraoperatively and via an intraarticular catheter postoperatively. the primary aim of this study is to evaluate if intra- and postoperative administration of ropivacaine, ketorolac and epinephrine into the operating field would affect hospital stay. secondary end-points were morphine consumption, pain intensity and side effects. in an attempt to assess the safety of this technique, knee function and patient satisfaction scores were assessed up to 6 months after surgery.

Eligibility criteria:
inclusion criteria: * patients scheduled for unicompartmental knee arthroplasty * aged 20-80 yrs. * asa physical status i-iii and mobility indicating normal postoperative mobilization exclusion criteria: * known allergy or intolerance to one of the study drugs * serious liver-, heart- or renal decease * rheumatoid arthritis * chronic pain or bleeding disorder

Keywords: postoperative pain local infiltration analgesia knee arthroplasty postoperative pain management following unicompartmental knee arthroplasty
safety of low dose iv contrast ct scanning in chronic kidney disease

Conditions: Chronic Kidney Disease; Pulmonary Embolism; Renal Artery Stenosis; Pulmonary Cancer

Summary: the purpose of this study is to show that the use of low volume iso-osmolar non-ionic radio contrast medium (30 cc) in a thoracic ct scanning procedure in a selected group of patients with chronic kidney disease (ckd) will avoid contrast induced nephropathy (cin) in comparison to a similar group of patients with ckd who receive no contrast medium..

the use of radio contrast medium enhances the image quality of ct scans. however, contrast ct is avoided in patients with ckd for fear of contrast-induced nephropathy. the current standard of care for these patients is ct without contrast. taking advantage of fast scanning capabilities of modern ct scanners (64-multi-detector ct), the current investigators have developed a method to use low volume iso-osmolar non-ionic radio contrast medium (30 cc) which can be used in a selected group of adult patients with mild to moderate stable ckd (egfr 16-60 ml/min/m\^2 for at least 12 months), who require thoracic ct imaging for diagnostic purposes. up to 100 patients who meet the inclusion/exclusion criteria will be randomized to standard care (no-contrast, 50 controls) or low volume contrast ct (50 intervention group). the peak increase of serum creatinine levels within 72 hours after the ct procedure will be measured as an outcome variable for comparison between the two groups, as well as a safety monitoring variable in the intervention group (25% increase is the upper threshold).

Eligibility criteria:
inclusion criteria: * subjects with documented stable chronic kidney disease (ckd) defined as a stable egfr 16-60 ml/min/m\^2 for ≥ 12 months; and * referred to ct scanning procedure to evaluate pulmonary embolism, pulmonary malignancy, acute aortic syndromes, or renal artery stenosis. exclusion criteria: * ckd stages 1, 2 and 5 * stage 3-4 congestive heart failure (chf) * irregular supraventricular tachycardia * allergic to iodinated radio contrast medium (rcm) * allergic to mucomyst * pregnancy * evidence of acute renal failure (arf) * serum bicarbonate either less than 20 meq/l or greater than 35 meq/l * hydration with a bicarbonate solution is contraindicated or considered unsafe by the subject's caring physicians